Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99 - NCT05594368RecruitingPhase 1
Test targeted radiation to treat recurrent ventricular tachycardia
This trial studies a radiation approach (called stereotactic body radiation therapy, or SBRT) to treat ventricular tachycardia (a dangerous heart rhythm) that keeps coming back. It aims to reduce the rhythm episodes in people who have already tried catheter ablation (a procedure to cauterize rhythm sources) or cannot have it.
OstravaAges 18 years+ - NCT05627232RecruitingPhase 1
Tazemetostat and palbociclib for relapsed or resistant AML
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05609994RecruitingPhase 1
Vorasidenib plus a peptide vaccine for recurrent low-grade glioma
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
Durham, North CarolinaAges 18 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT05590689RecruitingPhase 1/Phase 2
Light-activated treatment for recurring brain tumor
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
MünsterAges 18–75 - NCT05569980Enrolling by invitation
Study of rectal prolapse surgery in the Nordic region
This study looks at people who are having surgery for rectal prolapse. The goal is to learn more about outcomes and care for patients after surgery.
Aarhus NAges 18 years+ - NCT05557474Recruiting
Test of a lung cancer prognosis kit after early tumor removal
This study tests a lab “prognosis kit” to better predict how early-stage lung cancer may progress after the tumor has been fully removed. You may be asked to provide tumor samples and possibly blood/body fluid samples so researchers can validate the kit.
Taichung, TaiwanAges 20 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05576974RecruitingPhase 2
Test a dye used during surgery to find head and neck cancer
This trial tests whether a single dose of an imaging dye (given during surgery) can help doctors find the unknown origin of head and neck cancer and check safety. It may help guide surgery and biopsies when the primary cancer location hasn’t been identified.
Dallas, TexasAges 18–99 - NCT05557201Recruiting
Study causes of repeated early miscarriages
This study looks at people who have had repeated early pregnancy losses to find patterns that might explain why miscarriages keep happening. It mainly involves collecting and analyzing your medical information to better understand risk factors.
ParisAges 18–50 - NCT05576831Recruiting
Testing HPV and p53 to guide vulvar cancer surgery
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Vancouver, British ColumbiaAges 18 years+ - NCT05564494Recruiting
Surgery for repeat shoulder dislocations
This trial studies surgical treatment for people whose shoulder keeps dislocating forward (anteriorly). It may help by choosing a surgery plan for the amount of bone loss seen on scans, while excluding people with certain medical or instability patterns.
New York, New YorkAges 16–40 - NCT05588648RecruitingPhase 1/Phase 2
Vactosertib for recurrent or progressive bone cancer
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Cleveland, OhioAges 12 years+ - NCT05573893Recruiting
Real-world study of trastuzumab deruxtecan for HER2 breast cancer
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
AmbergAges 18–130 - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05518305Recruiting
Predicting recurrent stroke risk in people with artery narrowing
This study looks at blood markers and brain/artery scan results to predict who with intracranial artery narrowing is more likely to have another stroke. It may help doctors spot higher-risk people earlier and better target prevention.
Los Angeles, CaliforniaAges 30 years+ - NCT05522881Recruiting
Study of genetic changes in oropharyngeal cancer tumors
This study collects information and tumor tissue to look for genetic changes in oropharyngeal cancer, especially in patients whose cancer has come back. The goal is to better understand the disease and may help future treatment planning.
Kaohsiung CityAges 20 years+ - NCT05510167Recruiting
How quitting alcohol affects heart rhythm after ablation
This study looks at whether stopping alcohol after a heart procedure called catheter ablation helps prevent irregular heartbeats from coming back and improves your thinking and quality of life.
Austin, TexasAges 18–85
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.